ReWalk机器人技术 RWLK 深 沪
等待开盘 01-23 09:30:00 美东时间
1.0501
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 1.0501
- 总市值 6293.98万
- 52周最高 9.10
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.9228
- 委 比 0.00%
- 总股本 5993.70万
- 历史最高 7648.55
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.87
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多UPDATE: Lifeward To Acquire Oramed's POD Technology And Secure Up To $47M Strategic Investment As Oramed Takes Up To 49.99% Stake
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder
01-13 21:18
Oramed and Lifeward Announce Strategic Transaction
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward ...
01-13 20:58
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
Lifeward Ltd has secured up to $47 million in strategic investment from Oramed Pharmaceuticals and another investor to drive profitability and diversify its portfolio into biotech. Lifeward acquired Oramed's Protein Oral Delivery (POD™) technology, targeting the $600+ billion injectable drugs market, including the potential first oral insulin medicine, ORMD-0801. The transaction allows Lifeward to focus on existing MedTech products like ReWalk an...
01-13 13:00
Lifeward Appoints Bob Marshall as Chairman of the Board
Lifeward Ltd. announced that Bob Marshall has been appointed as Chairman of the Board, effective January 1, 2026, replacing Joseph Turk, who is transitioning to a new role at Fresenius Medical Care. CEO Mark Grant expressed gratitude for Turk's leadership and welcomed Marshall, highlighting his expertise and strategic insights. Marshall, currently CFO and Treasurer of Lantheus Holdings, has extensive experience in healthcare and finance. Lifeward...
2025-12-19 21:05
Lifeward Expands Patient Access To ReWalk Personal Exoskeleton Through New International Distribution Agreement With Verita Neuro
Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalitiesNew delivery model for ReWalk will integrate in-patient
2025-12-17 21:13
Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval
Humana and UnitedHealthcare, the two largest Medicare Advantage providers in the U.S., have approved coverage for the ReWalk 7 Personal Exoskeleton. This decision, following UnitedHealthcare's approval a few weeks ago, ensures better access to this life-changing technology for individuals with spinal cord injuries. The coverage reflects Humana's commitment to innovative medical solutions and will strengthen Lifeward's revenue and cash flow, suppo...
2025-12-03 13:00
Lifeward Gets First Prior Authorization From UnitedHealthcare Medicare Advantage Plan For ReWalk 7 Personal Exoskeleton
Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that it received
2025-11-17 21:05
Lifeward to Report Third Quarter Financial Results on November 14, 2025
<p>Lifeward Ltd. announced it will release its third quarter 2025 financial results on November 14, 2025, prior to market open. A conference call and webcast will be hosted by Mark Grant and Almog Adar at 8:30 a.m. EST to discuss the results. Access details, including toll-free numbers and an access code, are provided. The webcast will also be archived on the company’s website. Lifeward designs innovative medical technologies to improve the lives...
2025-11-10 12:00
First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton
Lifeward Ltd. announced its first payment from a commercial Medicare Advantage Plan for its ReWalk 7 Personal Exoskeleton. The company reported accelerated claim approval timelines, with most Medicare claims processed in 30-60 days. CMS finalized a Medicare reimbursement pathway for personal exoskeletons in 2024, leading to faster processing and reduced appeals.
2025-09-09 12:30
Lifeward Receives CE Mark For ReWalk 7 Exoskeleton; Expands Commercial Sales In Europe
Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that the company
2025-09-08 20:34
